Regeneron Pharmaceuticals is acquiring 23andMe for $256 million, gaining access to the genetic data of around 15 million customers. This raises data privacy concerns, despite assurances from Regeneron to honor existing privacy practices. The sale also brings up questions about potential compensation for customers if the data leads to profitable medications.
